Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

403 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Late presentation for HCV care: Time to target people with diabetes and/or hazardous alcohol use (ANRS CO22 HEPATHER cohort).
Santos M, Protopopescu C, Delarocque-Astagneau E, Bourlière M, Petrov-Sanchez V, Di Beo V, Larrey D, Baudoin M, Dorival C, Bureau M, Fontaine H, Carrat F, Marcellin F, Pol S, Carrieri P; ANRS CO22 HEPATHER study group. Santos M, et al. Among authors: carrat f. Liver Int. 2022 Jan;42(1):38-49. doi: 10.1111/liv.15056. Epub 2021 Sep 18. Liver Int. 2022. PMID: 34520614
Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, Morand P, Goujard C, Pialoux G, Piroth L, Salmon-Céron D, Degott C, Cacoub P, Perronne C; ANRS HCO2 RIBAVIC Study Team. Carrat F, et al. JAMA. 2004 Dec 15;292(23):2839-48. doi: 10.1001/jama.292.23.2839. JAMA. 2004. PMID: 15598915 Clinical Trial.
Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy.
Bani-Sadr F, Carrat F, Pol S, Hor R, Rosenthal E, Goujard C, Morand P, Lunel-Fabiani F, Salmon-Ceron D, Piroth L, Pialoux G, Bentata M, Cacoub P, Perronne C; ANRS Hc02-Ribavic Study Team. Bani-Sadr F, et al. Among authors: carrat f. J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):47-52. doi: 10.1097/01.qai.0000174649.51084.46. J Acquir Immune Defic Syndr. 2005. PMID: 16123681
Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment.
Bani-Sadr F, Carrat F, Rosenthal E, Piroth L, Morand P, Lunel-Fabiani F, Bonarek M, Colin de Verdiere N, Pialoux G, Cacoub P, Pol S, Perronne C; ANRS HC02-Ribavic Study Team. Bani-Sadr F, et al. Among authors: carrat f. Clin Infect Dis. 2005 Dec 15;41(12):1806-9. doi: 10.1086/498312. Epub 2005 Nov 11. Clin Infect Dis. 2005. PMID: 16288408 Clinical Trial.
Comparison of serum hepatitis C virus (HCV) RNA and core antigen levels in patients coinfected with human immunodeficiency virus and HCV and treated with interferon plus ribavirin.
Pivert A, Payan C, Morand P, Fafi-Kremer S, Deshayes J, Carrat F, Pol S, Cacoub P, Perronne C, Lunel F. Pivert A, et al. Among authors: carrat f. J Clin Microbiol. 2006 Feb;44(2):417-22. doi: 10.1128/JCM.44.2.417-422.2006. J Clin Microbiol. 2006. PMID: 16455894 Free PMC article. Clinical Trial.
Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors.
Bani-Sadr F, Carrat F, Bedossa P, Piroth L, Cacoub P, Perronne C, Degott C, Pol S; ANRS HC02 - Ribavic Study team. Bani-Sadr F, et al. Among authors: carrat f. AIDS. 2006 Feb 28;20(4):525-31. doi: 10.1097/01.aids.0000210606.63138.f5. AIDS. 2006. PMID: 16470116 Clinical Trial.
403 results